白云山:多产品新进入国家基药目录,相关营收占比0.64%

阿斯达克财经
Jul 10

7月10日|白云山公告,近日国家卫生健康委员会等发布《国家基本药物目录(2026年版)》,公司分公司白云山制药总厂、何济公药厂及子公司光华药业、天心制药、王老吉药业涉及产品新进入或退出该目录。其中小柴胡颗粒、舍曲林、头孢克肟颗粒等23个新品规新进入,同时氯喹、磺胺嘧啶、己烯雌酚、参苓白术散、盐酸克林霉素注射液等产品退出。2025年小柴胡颗粒(光华药业及王老吉药业)营业收入合计占公司2025年度营业...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10